LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

Well guys no worries here for the future. ps Spread the word!

brill week cant wait til monday!

Blue again! PING

RNS Number : 1486X
Provexis PLC
10 August 2009



10 August 2009




PROVEXIS PLC




('Provexis' or the 'Company')




Recent share price increase




Provexis plc notes the recent movement in its share price. The Board notes that, further to the Company's announcement of 28 May 2009, the final authorisation procedure by the European Commission in relation to Fruitflow, the Company's anti-thrombotic technology, is still under discussion. An update will be provided in due course.




ENQUIRIES




Provexis plc Tel.01753 752 290

Stephen Moon, CEO

Ian Ford, FD




Arbuthnot Tel.020 7012 2000

Tom Griffiths

Richard Johnson

What a day--brilliant we're on our way!!

moneyplus it dont get much better 3p plus tmrw!!!

managed to free up some money in to but not enough

RNS Number : 1886X
Provexis PLC
11 August 2009



11 August 2009

Provexis plc

('Provexis' or the 'Company')




COMMENCEMENT OF CLINICAL TRIAL FOR CROHN'S DISEASE





Provexis plc (PXS.L), the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, announces the commencement of a clinical trial for its NSP#3G plantain medical food for Crohns disease patients.

Our results announcement of 9 June 2009 updated the Clinical Trials Authorisation received from the Medicines & Healthcare products Regulatory Agency. We have since successfully completed the necessary pre-trial processes and can now announce a two-centre trial on Crohns disease patients in remission will commence on 18 August 2009. The trial will last for approximately 18 months, with 72 patients taking part.

Crohns disease is an inflammatory disease of the gastrointestinal tract causing a wide variety of symptoms. It affects between 400,000 and 600,000 in North America and estimates of incidence in Northern Europe range from 27 to 48 per 100,000 people. There is no known pharmaceutical or surgical cure for Crohns disease and treatment is restricted to controlling symptoms, maintaining remission and preventing relapse. The Company believes that its medical food technology will successfully maintain remission. The market for Crohns disease treatments is estimated at $1.7bn annually.


With the trial now starting and combined with recently obtained healthy human data, the Company will now commence seeking to identify potential global license or co-development partners to address this substantial market opportunity



Stephen Moon, Chief Executive Officer of Provexis plc, commented:




'Following our recent industry-first European Article 13(5) health claim approval for our Fruitflow anti-thrombotic technology, this further underpins Provexis' capability in developing high quality and scientifically-proven intellectual property. Our new technology addresses an important patient need for a debilitating disease where no effective medical food products for maintaining remission are available currently. Laboratory and human trial work to date has been very promising and we look forward to successful clinical data from this important trial.'







-ends-




For further information please contact:

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 752290




Tom Griffiths/Alasdair Younie Tel: 020 7012 2000

Arbuthnot Securities

was definately worth the wait - almost 5 years - and I'm willing to wait even more - this has a long way to go - we havn't even had final confirmation of EC nor the subsequent commercial agreements that are waiting in the wings though these feel like they are beginning to be priced in. well done everyone who kept the faith and posting updates - your reward is here.

Global, with everthing in the pipeline 10p will be a distant memory soon!!!

It's looking good...think I've been in for as long as 4/5 yrs also and have topped up recently at around 1p mark.... so it's nice to see this coming good... and hopefully a lot more to come !

good on everyone who held on for this. 1 out of 15 shares coming good makes it all worth while!

GN--quite agree I have had about 9 shares go suspended or bust--bb. wlw and various oilies like tom ive and eel! I have every hope this little gem will claw back my losses and more. Great news today and lots more to come.

Currently 14 mil more buys than sells this should be up more. Plus anybody else having problems getting on ad%fn

Yes---overwhelmed perhaps lol! sp holding steady despite all the buys.

14% up take that everyday

3 mil late reported trades angle offloading more held us back poss.

blanche - even 5% would be good...perceptions are becoming distorted....

Some people are talking about takeovers......not sure this makes any sense since the agreements with commercial partners as outlined in news and interims etc are all related to particular fields/markets and only for fruitflow. So coca cola has rights to beverage market excluding mini drinks, the guys selling sirco ( the name slips me) have rights to juices, unilever have/had rights to spreads. So there is no incentive for coke to takeover provexis. it has/will confirm a deal to license the product in a certain niche. DSM Venturing is the division that invests in new tech companies - i do not think they will launch a takeover. Angle have been supporting as start up investors and i presume felt their role was finished since pxs moved to a new phase. unilever seem to have dropped the ball by changing their market strategy.

I believe pxs will grow as an independent Rand D company ( they can recruit whichever staff they need) and continue to license out their intellectual property into niche markets. Coke Danone etc are not interested nor do they want to be involved in pure pharma and are here for the beneficial food market.

UK start-up Provexis is confident the European Commission, in consultation with member states, will issue consumer-friendly wording for its tomato extract blood circulation health claim.

Provexis is the only company to earn a positive article 13.5 opinion so far. Twelve others have failed to impress EFSA scientists for varying reasons including poor trial design and inappropriate claim wording.

http://www.nutraingredients.com/On-your-radar/Health-claims/EU-tomato-extract-health-claim-wording-gets-user-friendly-treatment